![Stuart Paynter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 700 973 $ in data 31/05/2026
Stuart Paynter currently works at Oxxon Therapeutics Ltd., as Director from 2017, Oxford Biomedica (UK) Ltd., as Secretary & Director, Ceres Power Holdings plc, as Chief Financial Officer & Director from 2024, and The Institute of Chartered Accountants in England & Wales, as Member.
Mr. Paynter also formerly worked at STERIS Ltd., as Finance Director-European Region from 2001 to 2007, Shire Pharmaceuticals Ltd., as Senior Director-Finance Business from 2007 to 2016, Oxford Biomedica Plc, as Chief Financial Officer & Director from 2017 to 2024, and De La Rue Plc, as Head-Finance Business Partnering from 2016 to 2021.
Mr. Paynter received his undergraduate degree from Imperial College London.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2025 | 47.682 ( 0,02% ) | 542 785 $ | 31/05/2026 | |
OXFORD BIOMEDICA PLC 0,02% | 31/12/2024 | 18.687 ( 0,02% ) | 158 188 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CERES POWER HOLDINGS PLC | Direttore Finanziario/CFO | 01/10/2024 |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Corporate Officer/Principal | - |
Oxford Biomedica (UK) Ltd.
 Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Develops novel gene therapy products and treatment for cystic fibrosis | Direttore/Membro del Consiglio | - |
Oxxon Therapeutics Ltd.
 Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Direttore/Membro del Consiglio | 29/08/2017 |
| Società | Posizione | Fine |
|---|---|---|
| OXFORD BIOMEDICA PLC | Direttore Finanziario/CFO | 02/09/2024 |
| DE LA RUE | Corporate Officer/Principal | 01/07/2021 |
Shire Pharmaceuticals Ltd.
 Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Direttore Finanziario/CFO | 01/02/2016 |
STERIS Ltd.
 STERIS Ltd. Medical SpecialtiesHealth Technology Manufactures surgical and other medical supplies | Corporate Officer/Principal | 01/07/2007 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
Ceres Power Holdings plc
 Ceres Power Holdings plc Electronic Production EquipmentElectronic Technology Engages in development and commercialization of fuel cell technology | Electronic Technology |
STERIS Ltd.
STERIS Ltd. Medical SpecialtiesHealth Technology Manufactures surgical and other medical supplies | Health Technology |
De La Rue Plc
 De La Rue Plc Commercial Printing/FormsCommercial Services Designs, manufactures and delivers bank notes and provide authentication software | Commercial Services |
Oxford Biomedica Plc
 Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Commercial Services |
Shire Pharmaceuticals Ltd.
Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Oxxon Therapeutics Ltd.
Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Develops novel gene therapy products and treatment for cystic fibrosis | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
